Chronic myelogenous leukemia: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
[[File:bcrablmet.jpg| | {{SI}} | ||
{{Infobox medical condition | |||
| name = Chronic myelogenous leukemia | |||
| image = [[File:bcrablmet.jpg|250px]] | |||
| caption = [[BCR-ABL]] fusion protein | |||
| field = [[Hematology]] | |||
| symptoms = [[Fatigue (medical)|Fatigue]], [[weight loss]], [[fever]], [[night sweats]], [[splenomegaly]] | |||
| complications = [[Blast crisis]], [[anemia]], [[thrombocytopenia]] | |||
| onset = Typically in [[adulthood]] | |||
| duration = [[Chronic (medicine)|Chronic]] | |||
| causes = [[Philadelphia chromosome]] (translocation between [[chromosome 9]] and [[chromosome 22]]) | |||
| risks = [[Radiation exposure]], [[age]], [[male]] gender | |||
| diagnosis = [[Complete blood count]], [[bone marrow biopsy]], [[cytogenetic analysis]] | |||
| differential = [[Chronic lymphocytic leukemia]], [[acute myeloid leukemia]], [[myeloproliferative neoplasms]] | |||
| treatment = [[Tyrosine kinase inhibitors]], [[chemotherapy]], [[stem cell transplant]] | |||
| prognosis = Generally good with treatment | |||
| frequency = 1-2 cases per 100,000 people per year | |||
}} | |||
[[File:Schematic of the Philadelphia Chromosome.svg|left|thumb|Schematic of the Philadelphia Chromosome]] [[File:Diagram showing which cells CML can start in CRUK 388.svg|left|thumb|Diagram showing which cells CML can start in CRUK 388.svg]] [[File:LMC4.jpg|left|thumb|LMC4]] [[File:Chronic Myeloid Leukemia smear 2009-04-09.JPG|left|thumb|Chronic Myeloid Leukemia smear 2009-04-09]] [[File:Hypolobated small megakaryocyte.jpg|thumb|Hypolobated small megakaryocyte|right]] '''Chronic myelogenous leukemia''' ('''CML'''), also known as '''chronic myeloid leukemia''', is a type of [[cancer]] that originates in the [[bone marrow]] and results in the overproduction of [[white blood cells]]. It is a form of [[leukemia]], which is a group of cancers that typically begin in the [[bone marrow]] and result in high numbers of abnormal [[white blood cells]]. | |||
== Pathophysiology == | == Pathophysiology == | ||
CML is characterized by the presence of the [[Philadelphia chromosome]], a specific genetic abnormality in chromosome 22 of [[human]] [[cells]]. This abnormality is a result of a translocation between chromosome 9 and chromosome 22, which creates the [[BCR-ABL]] fusion gene. The [[BCR-ABL]] gene produces a protein with tyrosine kinase activity that leads to uncontrolled cell division. | CML is characterized by the presence of the [[Philadelphia chromosome]], a specific genetic abnormality in chromosome 22 of [[human]] [[cells]]. This abnormality is a result of a translocation between chromosome 9 and chromosome 22, which creates the [[BCR-ABL]] fusion gene. The [[BCR-ABL]] gene produces a protein with tyrosine kinase activity that leads to uncontrolled cell division. | ||
Latest revision as of 01:53, 5 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Chronic myelogenous leukemia | |
|---|---|
| |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fatigue, weight loss, fever, night sweats, splenomegaly |
| Complications | Blast crisis, anemia, thrombocytopenia |
| Onset | Typically in adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Philadelphia chromosome (translocation between chromosome 9 and chromosome 22) |
| Risks | Radiation exposure, age, male gender |
| Diagnosis | Complete blood count, bone marrow biopsy, cytogenetic analysis |
| Differential diagnosis | Chronic lymphocytic leukemia, acute myeloid leukemia, myeloproliferative neoplasms |
| Prevention | N/A |
| Treatment | Tyrosine kinase inhibitors, chemotherapy, stem cell transplant |
| Medication | N/A |
| Prognosis | Generally good with treatment |
| Frequency | 1-2 cases per 100,000 people per year |
| Deaths | N/A |



Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a type of cancer that originates in the bone marrow and results in the overproduction of white blood cells. It is a form of leukemia, which is a group of cancers that typically begin in the bone marrow and result in high numbers of abnormal white blood cells.
Pathophysiology[edit]
CML is characterized by the presence of the Philadelphia chromosome, a specific genetic abnormality in chromosome 22 of human cells. This abnormality is a result of a translocation between chromosome 9 and chromosome 22, which creates the BCR-ABL fusion gene. The BCR-ABL gene produces a protein with tyrosine kinase activity that leads to uncontrolled cell division.
Symptoms[edit]
Common symptoms of CML include:
- Fatigue
- Weight loss
- Night sweats
- Fever
- Splenomegaly (enlarged spleen)
- Hepatomegaly (enlarged liver)
- Bone pain
Diagnosis[edit]
CML is typically diagnosed through a combination of blood tests, bone marrow biopsy, and cytogenetic analysis. The presence of the Philadelphia chromosome is a key diagnostic marker.
Stages[edit]
CML progresses through three phases:
- Chronic phase: The disease progresses slowly and patients may have mild symptoms.
- Accelerated phase: The disease progresses more rapidly and symptoms become more severe.
- Blast crisis: The disease behaves like an acute leukemia with rapid progression and severe symptoms.
Treatment[edit]
Treatment options for CML include:
- Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib.
- Chemotherapy
- Stem cell transplant
- Interferon therapy
Prognosis[edit]
The prognosis for CML has improved significantly with the advent of tyrosine kinase inhibitors. Many patients achieve long-term remission and have a normal life expectancy.
Epidemiology[edit]
CML accounts for about 15-20% of all cases of adult leukemia. It is more common in older adults, with the median age at diagnosis being around 65 years.
See also[edit]
References[edit]
<references group="" responsive="1"></references>

